Antihypertensive Drugs

Correct Answer

C — Glucagon-like peptide-1 receptor agonists

Rationale

Semaglutide, liraglutide, and dulaglutide are glucagon-like peptide-1 receptor agonists. Empagliflozin is a sodium-glucose cotransporter 2 inhibitor. Sitagliptin is a dipeptidyl peptidase 4 inhibitor. Glipizide is a sulfonylurea.

Correct Answer

A — Beta-adrenergic receptor antagonists

Rationale

Carvedilol and nebivolol are beta-adrenergic receptor antagonists. Amlodipine is a calcium channel blocker. Losartan is an angiotensin receptor blocker. Spironolactone is a mineralocorticoid receptor antagonist.

Correct Answer

D — Thiazide-like diuretic

Rationale

Indapamide is a thiazide-like diuretic. Bumetanide is a loop diuretic. Triamterene is a potassium-sparing diuretic. Acetazolamide is a carbonic anhydrase inhibitor.

Correct Answer

B — Selective beta-1 adrenergic receptor antagonists

Rationale

Nebivolol is a selective beta-1 adrenergic receptor antagonist. Propranolol is a nonselective beta-adrenergic receptor antagonist. Doxazosin is an alpha-1 adrenergic receptor antagonist. Methyldopa is a centrally acting alpha-2 adrenergic receptor agonist.

Correct Answer

C — Renin-angiotensin-aldosterone system inhibitors

Rationale

Lisinopril and losartan are both renin-angiotensin-aldosterone system inhibitors, though lisinopril is specifically an angiotensin converting enzyme inhibitor and losartan is specifically an angiotensin receptor blocker. Aliskiren is a direct renin inhibitor, a separate subclass within renin-angiotensin-aldosterone system inhibition. Spironolactone is a mineralocorticoid receptor antagonist. Amlodipine is a calcium channel blocker.

Correct Answer

A — Sodium-glucose cotransporter 2 inhibitor

Rationale

Empagliflozin is a sodium-glucose cotransporter 2 inhibitor. Liraglutide is a glucagon-like peptide-1 receptor agonist. Sitagliptin is a dipeptidyl peptidase 4 inhibitor. Metformin is a biguanide.

Correct Answer

D — Compensatory hyperinsulinemia activates the sympathetic nervous system and promotes renal sodium retention; angiotensin II from visceral fat worsens insulin resistance in skeletal muscle, and hyperglycemia stiffens arteries through advanced glycation end products that reduce nitric oxide bioavailability

Rationale

In type 2 diabetes, the pancreas compensates for insulin resistance by secreting more insulin — producing chronic hyperinsulinemia. Excess insulin has two blood-pressure-elevating effects beyond glucose regulation: it activates the sympathetic nervous system (raising cardiac output and peripheral resistance) and promotes sodium reabsorption via upregulated sodium-hydrogen exchanger activity in the proximal renal tubule (expanding plasma volume). Adipose tissue — particularly visceral fat — expresses all renin-angiotensin-aldosterone system components. Angiotensin II generated in visceral fat enters the systemic circulation and inhibits insulin receptor substrate-1 signaling in skeletal muscle, worsening insulin resistance and creating a self-reinforcing cycle between renin-angiotensin-aldosterone system activation and metabolic dysfunction. Simultaneously, chronic hyperglycemia generates advanced glycation end products that chemically modify proteins including endothelial nitric oxide synthase, reducing nitric oxide bioavailability, impairing arterial vasodilation, and stiffening arterial walls. These three parallel pathways — sympathetic, volume, and vascular — explain the high co-prevalence of type 2 diabetes and hypertension and the rationale for using renin-angiotensin-aldosterone system inhibitors as first-line therapy.

Correct Answer

B — Thiazide-induced hypokalemia impairs insulin secretion from pancreatic beta cells, since potassium channel closure is required for the membrane depolarization that triggers insulin release

Rationale

In pancreatic beta cells, normal glucose-stimulated insulin secretion depends on closure of adenosine triphosphate-sensitive potassium channels, which causes membrane depolarization, opening of voltage-gated calcium channels, and calcium-triggered insulin granule release. When serum potassium is low from thiazide-induced urinary potassium wasting, the electrochemical gradient across the beta cell membrane is altered, impairing the potassium channel closure step and reducing the calcium influx needed to trigger insulin release. The result is reduced insulin secretion in response to glucose — clinically manifesting as worsening glycemic control. This explains why the metabolic risk of thiazides is dose-dependent: higher doses cause more hypokalemia and greater impairment of beta cell function. The practical management strategies are to use the lowest effective dose, prefer indapamide or chlorthalidone over hydrochlorothiazide, and pair with a renin-angiotensin-aldosterone system inhibitor to blunt potassium wasting. Correcting potassium when thiazide-induced hypokalemia occurs also improves glycemic control.

Correct Answer

A — Beta-2 blockade in pancreatic beta cells impairs glucose-stimulated insulin secretion, and beta-2 blockade in skeletal muscle impairs glycogenolysis — delaying hypoglycemia recovery; diaphoresis is preserved because sweat gland stimulation is cholinergically mediated, not adrenergically mediated

Rationale

Beta-adrenergic receptor antagonists create two distinct metabolic hazards in insulin-treated or sulfonylurea-treated diabetic patients. First, beta-2 receptors on pancreatic beta cells normally facilitate insulin secretion; blocking them reduces insulin release and can cause mild hyperglycemia. Second, glycogenolysis in skeletal muscle and the liver — critical for recovering blood glucose during hypoglycemia — is stimulated by beta-2 receptor activation; blocking this delays the counter-regulatory response to hypoglycemia, prolonging and deepening episodes. The adrenergically mediated warning symptoms of hypoglycemia — tachycardia, palpitations, tremor — are also blocked, leaving patients without their usual alert. The critical exception is sweating: eccrine sweat glands are innervated by cholinergic sympathetic fibers that release acetylcholine rather than norepinephrine. Beta-adrenergic receptor blockade has no effect on cholinergic transmission, so diaphoresis remains intact and is the only reliable hypoglycemia warning in patients on non-selective beta-blockers. Non-selective agents carry more risk than cardioselective agents because they more completely block beta-2-mediated glycogenolysis.

Correct Answer

C — Calcium channel blockers are metabolically neutral — producing no adverse effects on glucose, insulin sensitivity, or lipids — and should be combined with rather than substituted for renin-angiotensin-aldosterone system inhibitors when albuminuria is present, since they have less antiproteinuric effect

Rationale

Calcium channel blockers — particularly dihydropyridines such as amlodipine — are metabolically neutral antihypertensives. They produce no adverse effects on glucose metabolism, insulin sensitivity, triglycerides, or high-density lipoprotein. This makes them safe and effective partners in combination antihypertensive regimens for patients with type 2 diabetes. When a patient with diabetic hypertension also has albuminuria, calcium channel blockers should be added to a renin-angiotensin-aldosterone system inhibitor — not substituted for it — because dihydropyridine calcium channel blockers have substantially less antiproteinuric effect than renin-angiotensin-aldosterone system inhibitors. The renoprotective mechanism of renin-angiotensin-aldosterone system inhibitors — dilating the efferent arteriole (the vessel exiting the glomerular capillary tuft) and reducing intraglomerular pressure — is not replicated by calcium channel blockers, which act primarily on systemic arterioles. The ACCOMPLISH trial demonstrated that the combination of a renin-angiotensin-aldosterone system inhibitor with amlodipine produced superior cardiovascular outcomes compared with the same renin-angiotensin-aldosterone system inhibitor combined with hydrochlorothiazide.

Correct Answer

D — An initial estimated glomerular filtration rate dip of 5 to 10 percent is expected and acceptable — it reflects reduced intraglomerular pressure from restored tubuloglomerular feedback, analogous to the creatinine rise seen with renin-angiotensin-aldosterone system inhibitor initiation, and does not indicate nephrotoxicity

Rationale

When empagliflozin blocks sodium-glucose cotransporter 2 in the proximal tubule, it increases sodium delivery to the macula densa (the specialized cells that detect tubular sodium concentration), which reactivates tubuloglomerular feedback and causes the afferent arteriole (the vessel supplying the glomerular capillary tuft) to constrict. This reduces intraglomerular hydrostatic pressure, which is the intended renoprotective effect. The lower intraglomerular pressure reduces the glomerular filtration rate modestly, producing a small measurable dip in estimated glomerular filtration rate. A reduction of 5 to 10 percent from baseline in the first weeks of therapy is expected, acceptable, and associated with better long-term renal outcomes — it is the pharmacological goal, not nephrotoxicity. This is conceptually identical to the acceptable creatinine rise seen when renin-angiotensin-aldosterone system inhibitors are started and dilate the efferent arteriole to reduce intraglomerular pressure from the other side. The drug should be continued with repeat assessment; discontinuation based on this expected early dip would deprive the patient of proven long-term renoprotection.

Correct Answer

B — Nonsteroidal anti-inflammatory drugs inhibit renal prostaglandin synthesis, raising blood pressure by 3 to 5 millimeters of mercury, blunting both diuretic and renin-angiotensin-aldosterone system inhibitor efficacy, and increasing the risk of acute kidney injury when combined with those agents

Rationale

Renal prostaglandins maintain afferent arteriolar vasodilation and support sodium excretion. When nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase enzymes, they reduce prostaglandin synthesis in the kidney, causing afferent arteriolar constriction, sodium retention, and blunted natriuretic responses to diuretics. The average blood pressure rise is 3 to 5 millimeters of mercury — clinically meaningful on top of a drug regimen already in use. Nonsteroidal anti-inflammatory drugs also antagonize the blood-pressure-lowering mechanism of renin-angiotensin-aldosterone system inhibitors, which partly depend on prostaglandin pathways for their vasodilatory and natriuretic effects. The combination of a nonsteroidal anti-inflammatory drug, a renin-angiotensin-aldosterone system inhibitor, and a diuretic — sometimes called triple whammy combination — carries a substantially elevated risk of acute kidney injury, particularly in diabetic patients who already have reduced nephron reserve. Preferred alternatives for pain in diabetic patients include acetaminophen for general pain, duloxetine or pregabalin for neuropathic pain, and topical diclofenac gel for localized musculoskeletal pain, which has much lower systemic absorption than oral formulations.

Correct Answer

A — Atenolol produced worse cardiovascular outcomes than losartan in a large hypertension trial despite equivalent blood pressure control; it carries a substantial metabolic burden worsening glucose and lipids; and it accumulates in chronic kidney disease due to renal elimination

Rationale

Three distinct problems make atenolol a poor choice in diabetic hypertension. First, the Losartan Intervention For Endpoint reduction in hypertension trial compared atenolol against losartan in hypertensive patients with left ventricular hypertrophy — despite equivalent blood pressure reduction, the losartan group had fewer strokes, fewer cases of new-onset diabetes, and greater regression of left ventricular hypertrophy. This demonstrated that atenolol's cardiovascular protection is weaker than that of renin-angiotensin-aldosterone system inhibitors even when blood pressure numbers are the same. Second, atenolol's beta-2 blockade impairs insulin secretion from pancreatic beta cells, delays glycogenolysis in hypoglycemia recovery, and raises triglycerides while lowering high-density lipoprotein — a metabolic burden that is particularly consequential in patients already predisposed to cardiovascular disease. Third, atenolol is almost entirely renally eliminated — it accumulates progressively as kidney function declines in diabetic nephropathy, increasing the risk of toxicity including bradycardia and heart block. Carvedilol, nebivolol, and bisoprolol are all preferable alternatives in this population.

Correct Answer

C — Glucagon-like peptide-1 receptor agonists lower blood pressure through substantial weight loss reducing volume-dependent hypertension, direct renal natriuresis via glucagon-like peptide-1 receptors in the kidney, and nitric oxide-mediated arterial vasodilation

Rationale

Glucagon-like peptide-1 receptor agonists produce blood pressure reduction through three complementary mechanisms. First, they cause substantial weight loss — typically 3 to 7 kilograms or more — which reduces the sympathetically driven and volume-dependent components of hypertension that are prominent in obese patients with type 2 diabetes. Second, glucagon-like peptide-1 receptors are expressed in renal proximal tubular cells, and receptor activation promotes natriuresis independent of glucose-lowering, directly reducing plasma volume. Third, glucagon-like peptide-1 receptor activation stimulates endothelial nitric oxide production, producing arterial vasodilation. Together these mechanisms produce the modest but consistent 2 to 5 millimeters of mercury systolic reduction observed in clinical trials. The primary clinical value of these agents in diabetic hypertension, however, is not blood pressure reduction per se but cardiovascular outcome benefit — reduction in major adverse cardiovascular events in patients with established cardiovascular disease or high cardiovascular risk, as demonstrated in dedicated outcome trials with liraglutide and semaglutide.

Correct Answer

B — An angiotensin converting enzyme inhibitor or angiotensin receptor blocker — because albuminuria signals early diabetic nephropathy, and these agents provide renoprotection beyond blood pressure lowering by reducing intraglomerular pressure, while also improving insulin sensitivity

Rationale

The presence of albuminuria — even at the microalbuminuria level of 30 to 300 milligrams per gram — signals early diabetic nephropathy and is the compelling indication for renin-angiotensin-aldosterone system inhibition as first-line therapy. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers reduce intraglomerular pressure by dilating the efferent arteriole (the vessel exiting the glomerular capillary tuft), thereby reducing the mechanical stress on the glomerular filtration barrier that drives proteinuria and glomerulosclerosis. This renoprotective effect is independent of blood pressure lowering — it occurs even when the same blood pressure reduction is achieved with other drug classes — and has been demonstrated in both type 1 and type 2 diabetic nephropathy trials. Additionally, by reducing angiotensin II levels, these agents remove angiotensin II-mediated interference with insulin receptor signaling in skeletal muscle, improving insulin sensitivity and reducing the risk of new-onset diabetes or disease progression in patients with established insulin resistance. Calcium channel blockers do not reduce intraglomerular pressure; they add blood pressure control but cannot substitute for renin-angiotensin-aldosterone system inhibitors when proteinuria is present.

Correct Answer

D — Metoprolol blocks beta-1 adrenergic receptors that mediate tachycardia and palpitations during hypoglycemia, masking these warnings; sweating is cholinergically mediated at eccrine glands and is not affected by beta-adrenergic receptor blockade, so it remains the one reliable warning sign

Rationale

During hypoglycemia, the sympathoadrenal system is activated: epinephrine is released and sympathetic nerves fire. Cardiac beta-1 receptor stimulation produces tachycardia and palpitations that normally alert the patient. Metoprolol, even at therapeutic doses as a cardioselective agent, blocks these beta-1-mediated cardiac responses — masking tachycardia and palpitations as hypoglycemia warning signs. Sweating during hypoglycemia, however, is mediated by acetylcholine released from sympathetic fibers that innervate eccrine sweat glands — a cholinergic pathway entirely unaffected by beta-adrenergic receptor blockade. Diaphoresis therefore remains intact and is the one dependable warning sign in patients on beta-adrenergic receptor antagonists. This patient had the textbook presentation: profuse sweating (cholinergic, preserved) with no tachycardia or palpitations (adrenergic, blocked by metoprolol). When beta-blockers are required in diabetic patients on insulin, patients and their families must be specifically counseled that sweating is the primary warning sign to monitor and that palpitations will be unreliable.

Correct Answer

A — Ibuprofen inhibits renal prostaglandin synthesis, reducing natriuresis and antagonizing the mechanisms by which both chlorthalidone and lisinopril lower blood pressure, while also increasing the risk of acute kidney injury in this combination

Rationale

Renal prostaglandins — particularly prostaglandin E2 and prostacyclin — maintain afferent arteriolar vasodilation and promote sodium excretion in the distal nephron. Ibuprofen inhibits cyclooxygenase enzymes throughout the body, reducing these renal prostaglandins. This impairs natriuresis at the distal tubule, directly counteracting the effect of chlorthalidone and contributing to sodium retention. It also antagonizes prostaglandin-mediated vasodilatory pathways that contribute to the antihypertensive mechanism of lisinopril, blunting renin-angiotensin-aldosterone system inhibitor efficacy. The average blood pressure rise from nonsteroidal anti-inflammatory drugs is 3 to 5 millimeters of mercury — sufficient to produce the observed 26 millimeter of mercury increase in this well-controlled patient. The combination of a nonsteroidal anti-inflammatory drug with a renin-angiotensin-aldosterone system inhibitor and a diuretic also carries elevated acute kidney injury risk in diabetic patients with already-reduced nephron reserve. Preferred alternatives for knee osteoarthritis include acetaminophen or topical diclofenac gel, which has substantially lower systemic cyclooxygenase inhibition than oral ibuprofen.

Correct Answer

C — Empagliflozin reduces cardiac preload through natriuresis, lowers intraglomerular pressure through tubuloglomerular feedback restoration, reduces visceral adiposity, and provides cardiovascular outcome benefit independent of its glucose-lowering effect — making it essential in type 2 diabetes with established cardiovascular disease

Rationale

Empagliflozin's cardiovascular and renal benefits are largely independent of blood glucose reduction. Its natriuretic effect from blocking proximal tubular sodium reabsorption reduces plasma volume and cardiac preload — a mechanism particularly beneficial in patients at risk for or with heart failure. By increasing sodium delivery to the macula densa and restoring tubuloglomerular feedback, it constricts the afferent arteriole (the vessel supplying the glomerular capillary tuft), reducing intraglomerular pressure and slowing diabetic nephropathy independently of glycemia. It also reduces visceral adiposity by 2 to 3 kilograms, removing a driver of sympathetic activation and renin-angiotensin-aldosterone system upregulation. Large cardiovascular outcome trials demonstrated that empagliflozin reduced the risk of cardiovascular death, heart failure hospitalization, and kidney disease progression in patients with type 2 diabetes and established cardiovascular disease — benefits that were consistent regardless of baseline hemoglobin A1c level, confirming that glycemic control alone does not account for these benefits. This is why current guidelines recommend empagliflozin and its class as essential add-on therapy in type 2 diabetes with cardiovascular disease, heart failure, or chronic kidney disease, prioritized alongside renin-angiotensin-aldosterone system inhibitors.